Search Results
You are looking at 1 - 1 of 1 items for
- Author: Malcolm David Cairns Donaldson x
Search for other papers by Sakina Kherra in
Google Scholar
PubMed
Search for other papers by Wendy Forsyth Paterson in
Google Scholar
PubMed
Search for other papers by Filiz Mine Cizmecioglu in
Google Scholar
PubMed
Search for other papers by Jeremy Huw Jones in
Google Scholar
PubMed
Search for other papers by Mariam Kourime in
Google Scholar
PubMed
Search for other papers by Heba Hassan Elsedfy in
Google Scholar
PubMed
Search for other papers by Sameh Tawfik in
Google Scholar
PubMed
Search for other papers by Andreas Kyriakou in
Google Scholar
PubMed
Search for other papers by Mohamad Guftar Shaikh in
Google Scholar
PubMed
Search for other papers by Malcolm David Cairns Donaldson in
Google Scholar
PubMed
Background
Hypogonadism is a key feature of Prader–Willi syndrome (PWS) but clear strategies for hormone replacement are lacking.
Objective
To evaluate the gonadal status and outcome in patients attending a Scottish PWS clinic from 1991 to 2019.
Methods
In 93 (35F:56M) patients, median follow-up 11.2 years, gonadal and pubertal status were assessed clinically. Pelvic ultrasound findings and basal/stimulated gonadotrophins were compared with age-matched controls.
Results
Females:of 22 patients aged > 11, 9 had reached B4–5, while 5 were still at B2–3, and 6 remained prepubertal. Eight patients experienced menarche aged 9.8–21.4 years, none with a normal cycle. Uterine length and ovarian volumes were normal but uterine configuration remained immature, with low follicular counts. Gonadotrophins were unremarkable, serum oestradiol 129 (70–520) pmol/L. Only 5 patients received oestrogen replacement. Males:fifty-four (96%) patients were cryptorchid (9 unilateral). Weekly hCG injections resulted in unilateral/bilateral descent in 2/1 of 25 patients. Of 37 boys aged > 11, 14 (9 with failed/untreated bilateral cryptorchidism) failed to progress beyond G1, 15 arrested at G2–3 (testes 3–10 mL), and 8 reached G4–5. Gonadotrophins were unremarkable except in boys at G2–5 in whom FSH was elevated: 12.3/27.3 vs 3.25/6.26 U/L in controls (P < 0.001). In males aged > 13, testosterone was 3.1 (0.5–8.4) nmol/L. Androgen therapy, given from 13.5 to 29.2 years, was stopped in 4/24 patients owing to behavioural problems.
Conclusion
Despite invariable hypogonadism, few females and only half the males with PWS in this study received hormone replacement. Double-blind placebo-controlled crossover trials of sex steroids are required to address unproven behavioural concerns.
